References
- Verbist L. In vitro activity of LY 146032, a new lipopeptide antibiotic, against Gram‐positive cocci. Antimicrob Agents Chemother 1987; 31: 340–342
- Ehlert F, Neu H C. In vitro activity of LY 146032 (daptomycin), a new peptolid. Eur J Clin Microbiol 1987; 6: 84–90
- Nagy E, Werner H, Heizmann W. In vitro activity of daptomycin metronidazole combinations against mixed bacterial cultures: reduced activity of metronidazole against Bacteroides species in the presence of Enterococcus faecalis. Eur J Clin Microbiol Infect Dis 1990; 9: 287–291
- Ullman U. In vitro Untersuchungen zum Synergismus von Metronidazole und Mezlocillin gegenüber Enterobacteriaceae und aerob‐anaeroben Mischpopulationen. Fortschr Antimicrob Antineoplat Chemother 1983; 24: 563–567
- Washington J A, II, Sutter V L. Dilution susceptibility test: agar and macro‐broth dilution procedures. Manual of clinical microbiology, E H Lennette, A Balows, W J Hausler, Jr, J P Traut. American Society for Clinical Microbiology, Washington, DC 1980; 453–548
- Wilkins T D, Chalgren S. Medium for use in antibiotic susceptibility testing of anaerobic bacteria. Antimicrob Agents Chemother 1976; 10: 926–928
- Escamilla J. Susceptibility of Haemophilus influenzae to ampicillin as determined by use of modified one minute beta‐lactamase test. Antimicrob Agents Chemother 1976; 9: 196–198
- Werner H. Kombination von Acylureidopenicillinen mit metronidazole bei Anaerobiern und anaerobaeroben Mischkulturen. Securopen, Baypen: Simultane Anwendung mit anderen Wirkstoffen, B Wiedemann, J Hengstmann, D Adam. Schattauer Verlag, Stuttgart, New York 1984; 25–40
- Heizmann W R, Schmidt R, Heilmann F, Werner H. Association experiment with aerobic anaerobic pathogens: a model of in vitro susceptibility testing in mixed infections. Activity of enoxacin, clindamycin and metronidazole. Infection 1989; 17: 160–164
- Jorgensen J H, Maher L A, Redding J S. In vitro activity of LY 146032 (daptomycin) against selected aerobic bacteria. Eur J Clin Microbiol 1987; 6: 91–95
- Soriano F, Ponte M C, Santamaria M. Activity of cefotaxime and metronidazole against Bacteroides and Escherichia coli alone and in mixed culture. J Antimicrob Chemother 1983; 12: 89–92
- Soriano F, Ponte M C. Comparative activities of aztreonam and cefotaxime against Escherichia coli and Bacteroides spp. in pure and mixed cultures. Antimicrob Agents Chemother 1984; 26: 39–41
- Gisby J, Beal A S. Comparative efficacies of amoxicillin‐clavulanic acid and ampicillin‐sulbactam against experimental Bacteroides fragilis, Escherichia coli mixed infections. Antimicrob Agents Chemother 1988; 32: 1830–1833
- Chrystal E JT, Koch R L, McLafferty M A, Goldman P. Relationship between metronidazole metabolism and bactericidal activity. Antimicrob Agents Chemother 1980; 18: 566–573
- McLafferty M A, Koch R L, Goldman P. Interaction of metronidazole with resistant and susceptible Bacteroides fragilis. Antimicrob Agents Chemother 1982; 21: 131–134
- Soriano F, Ponte M C, Gaspar M C. Reciprocal antimicrobial synergism between Escherichia coli and Bacteroides fragilis in the presence of metronidazole. J Clin Pathol 1982; 35: 1150–1152
- Onderdonk A B, Kasper D L, Mansheim B J. Experimental animal models for anaerobic infections. Rev Infect Dis 1979; 1: 291–301
- Tunér K, Nord C E. Beta‐lactamase‐producing anaerobic bacteria in recurrent tonsillitis. J Antimicrob Chemother 1982; 10(Suppl. A)153–156
- Hagen J C, Wood W S, Hashimoto T. In vitro stimulation of Bacteroides fragilis growth by Escherichia coli. Eur J Clin Microbiol 1982; 1: 338–343
- Namavar F, Verweij‐van Vught A MJJ, Bal M, van Steenbergen T JM, de Graaff J, Maclaren D M. Effect of anaerobic bacteria on killing of Proteus mirabilis by human polymorphonuclear leucocytes. Infect Immun 1983; 40: 930–935
- Verweij‐van Vught A MJJ, Namavar F, Vel W AC, Sparrius M, Maclaren D M. Pathogenic synergy between Escherichia coli and Bacteroides fragilis and B. vulgatus in experimental infections: a non‐specific phenomenon. J Med Microbiol 1986; 21: 43–47
- Brook I. In vitro susceptibility and in vivo efficacy of antimicrobials in the treatment of Bacteroides fragilis—Escherichia coli infections in mice. J Infect Dis 1989; 160: 651–656